Loading
A phase 3 trial of Daraxonrasib, Gemcitabine, Paclitaxel / nab-paclitaxel in pancreatic ductal adenocarcinoma, run by Revolution Medicines, Inc., now recruiting.
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma is a phase 3 interventional study registered as NCT07805954 by Revolution Medicines, Inc., with 400 participants planned, started 2026-08-28 and due to reach its primary completion in 2029-03. Interventions recorded: daraxonrasib, gemcitabine, nab-paclitaxel, zoldonrasib. Conditions listed: Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.
Shares Revolution Medicines, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, Daraxonrasib, KRAS & RAS inhibitors.
Shares Zoldonrasib, Revolution Medicines, KRAS mutation subtypes (G12C, G12D, G12V), KRAS & RAS inhibitors.
Shares Zoldonrasib, Revolution Medicines, Daraxonrasib, Paclitaxel / nab-paclitaxel.
Shares Revolution Medicines, KRAS mutation subtypes (G12C, G12D, G12V), Daraxonrasib, KRAS & RAS inhibitors.
Shares Zoldonrasib, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, Daraxonrasib, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question.
Shares Zoldonrasib, Revolution Medicines, Daraxonrasib, KRAS & RAS inhibitors.
Shares Revolution Medicines, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, Daraxonrasib, KRAS & RAS inhibitors.
Shares Revolution Medicines, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, Daraxonrasib, KRAS & RAS inhibitors.